Healthcare Industry News: erectile dysfunction
News Release - April 21, 2008
VIVUS Appoints Charles J. Casamento to the Board of DirectorsMOUNTAIN VIEW, Calif.--(HSMN NewsFeed)--VIVUS, Inc. (NASDAQ:VVUS ) announced today that it has appointed Charles J. Casamento to serve on the Board of Directors. Mr. Casamento has over 38 years of experience in the pharmaceutical and biotech industries. He was CEO for Osteologix, Interneuron and RiboGene, and he held executive positions in Sandoz, Roche, Johnson & Johnson, American Hospital Supply Corporation and Genzyme.
“Chuck is an industry veteran who brings excellent knowledge and diverse experience as a CEO and a director of small cap healthcare companies. In addition, his executive experience at large pharmaceutical companies will add to the level of talent that currently exists on our Board,” stated Leland Wilson, president and chief executive officer of VIVUS. “In his 38 years Chuck has completed over 70 transactions including mergers, acquisitions, divestitures, product licensing and R&D collaborations. He also took four companies public and completed several rounds of VC private financing. This experience will be helpful as we look to the future of VIVUS.”
Mr. Casamento is currently Executive Director and Principal for The Sage Group, a healthcare advisory group specializing in mergers, acquisitions and partnerships between biotechnology companies and pharmaceutical companies and he serves on the Boards of Directors of SuperGen Inc. and Cortex Pharmaceuticals. He holds an MBA, a B.Sc. (Pharm) and is a registered pharmacist.
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products. The current portfolio includes investigational products addressing obesity and sexual health. The pipeline includes: Qnexa™, which is in phase 3 for obesity and phase 2 for diabetes; Luramist (Testosterone MDTS®), for which a phase 2 study has been completed for the treatment of Hypoactive Sexual Desire Disorder (HSDD); and avanafil, for which a phase 2 study has been completed for the treatment of erectile dysfunction (ED). MUSE® is approved and currently on the market for the treatment of ED. For more information on clinical trials and products, please visit the company's web site at http://www.vivus.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.